129
Participants
Start Date
June 30, 2012
Primary Completion Date
May 31, 2018
Study Completion Date
August 31, 2018
Tesamorelin
Daily 2 mg subcutaneous injections of tesamorelin
Placebo-Control
3.0 mL vials
Capital Medical Associates, PC, Washington D.C.
Orange County Health Department, Orlando
Rowan Tree Medical , P.A., Wilton Manors
Gary J. Richmond, M.D., PA, Fort Lauderdale
Triple O Research Institute, West Palm Beach
Southampton Clinical Research, Inc d.b.a. Central West Clinical Research, St Louis
Southampton Healthcare, Inc., St Louis
Harold Hamm Diabetes Center at the University of Oklahoma, Oklahoma City
Dallas VA Medical Center, Dallas
UT Southwestern Medical Center, Atten: HIV Research Unit, Dallas
Research Access Network, Houston
St. Hope Foundation, Inc., Bellaire
Central Texas Clinical Research, Austin
Southwest Center for HIV/AIDS, Phoenix
Spectrum Medical Group, Phoenix
5P21 Rand Schrader Clinic, Los Angeles
University of California CARE Clinic, Los Angeles, Los Angeles
UCSD Antiviral Research Center, San Diego
Palmtree Clinical Research, Inc., Palm Springs
VAMC, Infectious Disease Section 111W, San Francisco
Fanno Creek Clinic, LLC, Portland
Virginia Mason Medical Center, Seattle
Be Well Medical Center, P.C., Berkley
South Jersey Infectious Disease, Somers Point
Lead Sponsor
Theratechnologies
INDUSTRY